SCHEMBL6354558

SCHEMBL6354558

CS(=O)(=O)c1ccc(-n2nc(C(N)=O)c3ccc4ccc(NC(=O)c5ccccc5Cl)cc4c32)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.44
AVPR2 P30518 1/20 0.43
GPR27 Q9NS67 1/20 0.43
USP28 Q96RU2 2/20 0.42
MAPT P10636 4/20 0.42
RAB9A P51151 2/20 0.42
GAA P10253 1/20 0.42
JAK2 O60674 2/20 0.42
JAK1 P23458 2/20 0.42
SMO Q99835 2/20 0.42
ALB P02768 1/20 0.41
HTR1A P08908 1/20 0.41
SLC6A2 P23975 1/20 0.41
PDE4A P27815 1/20 0.41
OPRM1 P35372 1/20 0.41
DRD3 P35462 1/20 0.41
HTR2B P41595 1/20 0.41
SLC6A3 Q01959 1/20 0.41
PDE4D Q08499 1/20 0.41
SHH Q15465 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6352335 0.93 JAK2 (0.44) KMT2AAVPR2GPR27USP28MAPT
SCHEMBL6340626 0.92 KMT2A (0.55) KMT2AJAK2JAK1POLBALDH1A1
SCHEMBL6353442 0.90 CRACR2A (0.43) KMT2AMAPTRAB9AGAATP53
SCHEMBL6345063 0.90 RAB9A (0.43) KMT2AMAPTRAB9AJAK2JAK1
SCHEMBL6342495 0.89 IKBKB (0.51) KMT2AUSP28MAPTRAB9AGAA
SCHEMBL6343763 0.88 IKBKB (0.49) KMT2AMAPTRAB9AJAK2JAK1
SCHEMBL6340636 0.87 PTGES (0.43) KMT2APTGS2
SCHEMBL6345452 0.86 KMT2A (0.48) KMT2AMAPTRAB9AJAK2JAK1
SCHEMBL6350930 0.85 KMT2A (0.46) KMT2ARAB9AJAK2JAK1PCTP
SCHEMBL6344425 0.83 IKBKB (0.45) KMT2AMAPTRAB9AJAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1438293-A2 SUBSTITUTED PYRAZOLYL BENZENESULFAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2004-07-21 EP claimed
US-20030125361-A1 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-07-03 US claimed
WO-2003027075-A2 SUBSTITUTED PYRAZOLYL BENZENESULFAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2003-04-03 WO claimed
US-6849653-B2 1H-benzo(g)indazole compounds as anticarcinogenic agents and also treat arthritis PHARMACIA CORPORATION (US) 2005-02-01 US disclosed
EP-1438293-A2 SUBSTITUTED PYRAZOLYL BENZENESULFAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2004-07-21 EP disclosed
US-20030125361-A1 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-07-03 US disclosed
WO-2003027075-A2 SUBSTITUTED PYRAZOLYL BENZENESULFAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125361-A1 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation IRAK4, NLRP3, CXCL8 KMT2A 2374/4885AVPR2 4443/4885GPR27 2532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.